Decreten en es it fr

Decreten Brand names, Decreten Analogs

Decreten Brand Names Mixture

  • Viskazide 10/25tab (Hydrochlorothiazide + Pindolol)
  • Viskazide 10/50tab (Hydrochlorothiazide + Pindolol)

Decreten Chemical_Formula


Decreten RX_link

Decreten fda sheet

Decreten msds (material safety sheet)

Decreten MSDS

Decreten Synthesis Reference

No information avaliable

Decreten Molecular Weight

248.321 g/mol

Decreten Melting Point

167-171 oC

Decreten H2O Solubility

7880 mg/L

Decreten State


Decreten LogP


Decreten Dosage Forms


Decreten Indication

For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.

Decreten Pharmacology

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Decreten Absorption

Rapidly and reproducibly absorbed (bioavailability greater than 95%).

Decreten side effects and Toxicity

LD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.

Decreten Patient Information

Decreten Organisms Affected

Humans and other mammals